D-type Cyclins and Cancer

Provides emphasis on functional aspects of D-type cyclins on mammalian tissue Reviews existing mouse models of cyclin D-deficiency Discusses potential of D-type cyclins as feasible therapeutic cancer targets

Provides emphasis on functional aspects of D-type cyclins on mammalian tissue Reviews existing mouse models of cyclin D-deficiency Discusses potential of D-type cyclins as feasible therapeutic cancer targets Includes supplementary material: sn.pub/extras

Autorentext

Philip W. Hinds is Professor and Chair of the Department of Developmental, Molecular and Chemical Biology at Tufts University School of Medicine. He is also the Deputy Director of Tufts Medical Cancer Center. Dr. Hinds is an expert in cell cycle control and its dysregulation in cancer cells. He participates in several journal editorial boards including the Journal of Biological Chemistry, the Chinese Journal of Cancer, and Cancer Research to name a few.

Nelson E. Brown is currently Associate Professor at the University of Talca School of Medicine in Chile. He is also Director of the Center for Medical Research at the University of Talca. His current work focuses on the role of cyclin D1-associated kinase activity in senescence and tumorigenesis

Inhalt
The D-type Cyclins: A Historical Perspective.- Mammalian Development and Cancer A Brief History of Mice Lacking D-type Cyclins or Cdk4/6.- D-type Cyclins and Gene Transcription.- Splice Variants and Phosphorylated Isoforms of Cyclin D1 in Tumorigenesis.- Cyclin D1, Metabolism, and the Autophagy-Senescence Balance.- Shifting a Paradigm: Cyclin D Activates pRb by Mono-Phosphorylation.